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Abstract  
 
The reduction of luvastatin (FLV) at a hanging mercury-drop electrode (HMDE)    
was    studied    by    square-wave    adsorptive-stripping    voltammetry (SWAdSV).  
FLV  can  be  accumulated  and  reduced  at  the  electrode,  with  a maximum  peak  
current  intensity  at  a  potential  of  approximately  -1.26 V  vs. AgCl=Ag, in an 
aqueous electrolyte solution of pH 5.25. The method shows lin- earity between peak 
current intensity and FLV concentration between 1.0 x 10-8 and  2.7 x 10-6 mol  L-1.  
Limits  of  detection  (LOD)  and  quantification  (LOQ) were found to be 9.9 x 10-9 
mol L-1  and 3.3 x 10-8 mol L-1, respectively. 
Furthermore, FLV oxidation at a glassy carbon electrode surface was used for 
its hydrodynamic monitoring by amperometric detection in a flow-injection system.  
The  amperometric  signal  was  linear  with  FLV  concentration  over  the range  1.0 x 
10-6   to  1.0 x 10-5 mol  L-1,  with  an  LOD  of  2.4 x 10-7 mol  L-1 and  an  LOQ  of  
8.0 x 10-7 mol  L-1.  A  sample  rate  of  50  injections  per  hour was achieved. 
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INTRODUCTION 
 
Nowadays, statins are the most effective antihypercholesterolemic agents 
used worldwide (Paoletti, Corsini, and Bellosta 2002; Schachter 2004). 
These compounds reduce levels of circulating atherogenic lipoproteins 
by competitive inhibition of HMG-CoA redutase, the rate-limiting enzyme 
in the synthesis of cholesterol (Endo 2004). Fluvastatin (FLV, Fig. 1) is one 
of these lipid-lowering drugs and the first entirely synthetic  statin. 
No official quantification methods are reported in the various phar- 
macopoeias. The majority of the methods proposed for the determination 
of FLV are based on separation methods and are applied in the analysis 
of serum or plasma samples. In Table 1, a summary of these methods is 
indicated, including some performance parameters. Several authors pro- 
pose the analysis of the racemates of FLV (Toreson and Eriksson 1996, 
1997; Lanchote et al. 2001; Di Pietro et al. 2006), and in one case several 
metabolic products were also analysed (Nakashima et al. 2001). 
Besides the methods included in Table 1, two electroanalytical proce- 
dures are also described (Ozkan and Uslu 2002; Dogan et al. 2007), which 
are based on the electro-oxidative behaviour of FLV in aqueous solution 
using  either  a  glassy-carbon  (Ozkan  and  Uslu  2002)  or  a  boron-doped 
diamond  (Dogan  et  al.  2007)  working  electrode.  The  methods  showed 
similar  linear  ranges  (10-4  to  10-6 mol  L-1)  with  limits  of  detection  at 
submicromolar  levels  and  were  applied  to  pharmaceutical  and  spiked 
human  serum  samples.  Until  now,  no  determination  of  FLV  based  on 
its  electroreduction  has  been  described,  and  also  no  hydrodynamic 
monitoring using electrochemical detection has been reported. 
 
 
 
 
Figure 1.  Chemical structure of Fluvastatin. 
 
Table 1. Analytical methods developed for the analysis of fluvastatin in serum= 
plasma and=or pharmaceutical products 
 
 
Methoda 
 
Detectiona 
Linear range 
(nmol L-1) 
LOQ 
(nmol L-1) 
 
Reference 
GC MS 5–1247 4.9 Leis and Windischhofer 2005 
LC FL 1–2436 — Al-Rawithi et al. 2003 
  1–244 1.2 Um et al. 2006 
  1–5000 0.5 Toreson and Eriksson 1996 
  0.5–3200 0.5 Toreson and Eriksson 1997 
  2–1523 1.8 Lanchote et al. 2001 
 MS 4–2436 3.7 Di Pietro et al. 2006 
  5–1218 4.9 Nirogi et al. 2006 
 UV 24–2436 24 Nakashima et al. 2001 
CE 
UV 
UV (1.0–5.2) x 104 
(2.4–6.8) x 104 
2900 
— 
Dogrukol-Ak et al. 2001 
Erk 2002 
aGC, gas chromatography; LC, liquid chromatography; CE, capillary electro- 
phoresis; UV, ultraviolet spectrophotometry; MS, mass spectrometric; FL, 
fluorimetric. 
 
In the present study, two methodologies for the quantification of 
FLV in a pharmaceutical product are proposed. Both methods are based 
on the electrochemical behavior of FLV. Square-wave adsorptive- 
stripping voltammetry (SWAdSV) was used under batch conditions, 
and amperometric detection was included in a flow injection analysis 
system (FIA-EC). 
 
 
EXPERIMENTAL 
 
Apparatus 
 
Voltammetric measurements, using SWV and SWAdSV, were performed 
using an Autolab PGSTAT12 (Metrohm-EcoChemie) potentiostat, con- 
trolled by a PC running GPES 4.9 software (Metrohm-EcoChemie), and 
a Metrohm 663 VA stand containing a three-electrode cell (all Metrohm). 
This   voltammetric   cell   consisted   of  a   multimode   mercury   working 
electrode,  used  in  the  hanging  mercury-drop  position  (HMDE),  an 
Ag=AgCl=KCl 3 mol L-1  reference electrode, and a glassy carbon auxili- 
ary electrode. 
In the single-manifold FIA system, solutions were transported to the 
amperometric detection cell by a Gilson Miniplus 3 peristaltic pump, using 
PTFE  tubing  (i.d.  0.8 mm).  Samples  and  standards  (Vinj ¼ 238.6 mL) 
 
were introduced into the carrier stream through a six-port Rheodyne 5041 
injection  valve.  Amperometric  detection  was  carried  out  in  a  Metrohm 
656 wall-jet cell coupled to a Metrohm 641 VA-detector. Working, refer- 
ence,  and  auxiliary  electrodes  were  glassy  carbon,  Ag=AgCl=KCl  3 mol 
L-1, and gold, respectively. The output signals were recorded on a Kipp 
& Zonnen BD 111 strip chart recorder. When required, the glassy carbon 
electrode was cleaned mechanically by polishing its  surface  with Al2O3 
with a particle size of 0.015 mm (BDH Chemicals) on a  wet polishing 
cloth. Flow injection signals were evaluated in  terms  of  peak  height 
(cm)  and afterward  converted  into  current (mA). 
 
Reagents and Solutions 
 
A FLV sodium standard was purchased from Calbiochem and used without 
further purification. Stock solutions of FLV (1.0 x 10-3 mol L-1) were pre- 
pared in water and stored in the dark at 4oC. All chemicals used were of ana- 
lytical reagent-grade quality. Deionized water (conductivity <0.1 mS cm-1) 
was obtained from a Millipore Simplicity-185 system. 
For SWAdSV, working solutions were diluted with water and electro- 
lyte solution to furnish the desired concentration. Two different buffers 
were tested in electrolyte pH optimization, a Britton-Robinson buffer 
(pH 1.9–11.8) (Fern'andez and Martin 1977) and an acetate (pH 4.5–6.0; 
0.2 mol  L-1)  buffer.  For  FIA,  solutions  were  prepared  by  diluting  the 
stock solution with electrolyte to furnish the desired concentrations and 
were injected into the carrier stream (Britton-Robinson buffer, pH 10.0). 
 
Procedures 
 
General Procedure 
 
In SWAdSV, the supporting electrolyte (10.00 mL) was purged with 
oxygen-free nitrogen for 300 s and for 3 s in subsequent scans. After the 
oxygen removal, accumulation of FLV at the electrode surface was per- 
formed, and a square-wave potential scan in the negative direction was 
applied. 
Using FIA-EC, the background current (baseline) was recorded 
continuously while the electrolyte flowed through the detection cell. 
 
Validation Procedure 
 
Several operational parameters of both methods were studied and 
optimized  for  FLV  determination.  Using  the  optimal  experimental 
 
conditions, validation of the methods was performed via evaluation of 
the linear range, limit of detection (LOD), limit of quantification 
(LOQ), repeatability, intermediate precision, accuracy, and selectivity. 
Repeatability and intermediate precision were assessed at three con- 
centrations.  For  repeatability  assays,  five  measurements  of  each  solu- 
tion  were  made  in  a  short  period  of  time;  to  determine  intermediate 
precision,  the  solutions  were  analyzed  for  3  consecutive  days.  For  the 
SWAdSV method, concentrations of 1.0 x 10-7 mol L-1, 1.3 x 10-6 mol 
mol L-1, and 2.5 x 10-6 mol L-1  were used. The precision of the FIA- 
EC method was evaluated by use of 2.0 x 10-6  mol L-1, 5.0 x 10-6 mol 
L-1, and 8.0 x 10-6 mol L-1  FLV solutions. To assess the accuracy and 
selectivity, known amounts of the pure drug were added to solutions of 
the pharmaceutical product at three concentration levels. In the evalua- 
tion of the SWAdSV method, a solution of the pharmaceutical contain- 
ing  1.0 x 10-7 mol  L-1  FLV  was  spiked  with  FLV  standard  to  furnish 
final  concentrations  of  5.0 x 10-7 mol  L-1,  1.5 x 10-6 mol  L-1,  and 
2.5 x 10-6 mol  L-1. For  the flow-injection  method,  FLV standard con- 
centration   levels   of   1.0 x 10-6    mol   L-1,   4.0 x 10-6    mol   L-1    and 
7.0 x 10-6     mol   L-1     were   added   to   volumetric   flasks   containing 
1.0 x 10-6 mol  L-1  of  FLV. 
 
Pharmaceuticals Analysis 
 
The methods were used to quantify FLV sodium in a pharmaceutical 
dosage form (Lescol-Novartis), containing 20 mg of FLV per capsule. 
Lescol contains the excipients magnesium stearate, gelatine, microcrystal- 
line cellulose, pregelatinized starch, red iron oxide, sodium lauryl 
sulphate, talc, titanium dioxide, and yellow iron oxide, among others. 
The content of one capsule was dissolved in 500.0 mL of water by 
sonication for 30 min (solution A). 
For  batch  analysis,  the  resulting  solution  was  diluted  100-fold 
with water, and an adequate volume of this diluted solution was added 
to  10.00 mL  of  electrolyte  contained  in  a  voltammetric  cell  to  achieve 
an   FLV   concentration   of   1.0 x 10-7 mol   L-1.   Using   the   standard 
addition method, increasing quantities of FLV standard between 0 and 
1.3 x 10-7 mol  L-1   were  added  to  the  solution  in  the  voltammetric 
cell. This procedure was repeated in triplicate. The use of the standard 
addition  method  and  the  large  dilution  make  the  filtration  of  solution 
A unnecessary. 
For hydrodynamic detection, an accurate volume of solution A, cor- 
responding  to  a  final  FLV  concentration  of  5.0 x 10-6 mol  L-1,  was 
transferred to a 10.00-mL volumetric flask. The volume was completed 
 
with  Britton-Robinson  buffer, pH  10.0.  The  quantification  was  carried 
by  interpolation  of  a  calibration  curve  (1.0 x 10-6 mol  L-1   to  1.0 x 
10-5 mol L-1). This procedure was repeated in triplicate. Again, no addi- 
tional treatment of the samples was required. 
 
 
RESULTS  AND DISCUSSION 
 
Square-Wave Adsorptive-Stripping Voltammetry (SWAdSV) 
 
The electrochemical behaviour of FLV was studied at an HMDE under 
batch conditions by SWV and SWAdSV. FLV was reduced in aqueous med- 
ium at the HMDE over a wide pH range (3.1–11.8, Britton-Robinson buf- 
fer). The analytical signal increased with increasing electrolyte pH up to pH 
5.25. After comparison with an acetate buffer (pH 4.5–6.0), results showed 
that the highest and best-defined peak was obtained at pH 5.25, which was 
chosen as supporting electrolyte in all further experiments. At this pH value, 
FLV presented a reduction peak at approximately -1.26 V, which increased 
with  increasing  accumulation  time  (tacc).  For  a  1.0 x 10
-6 mol  L-1  FLV 
solution, this increase is significant for up to approximately 130 s at an opti- 
mized  accumulation  potential  (Eacc)  of -0.3 V.  For  longer  accumulation 
times, the increase of ip  levels off, possibly due to the saturation coverage 
of the drop and=or competitive adsorption. The best compromise between 
ip and analysis time was achieved with a tacc of 30 s. The square-wave poten- 
tial scan was optimized regarding frequency (f ), pulse step (DEs), and pulse 
amplitude  (DEp); these  parameters  are  interrelated  and  have a  combined 
effect  on  the  analytical  signal.  Different  values  for  f  (50–1000 Hz),  DEs 
(1–5 mV), and DEp  (10–50 mV)were studied. The best relation among peak 
current intensity, peak definition, and repeatability was achieved with the 
follow conditions: f ¼ 500 Hz, DEs ¼ 5 mV, and DEp ¼ 50 mV. These condi- 
tions were used in all subsequent studies. 
A  linear  relationship  between  stripping  peak  current  intensity  and 
FLV  concentration  was  obtained  for  the  interval  between  1.0 x 10-8 
and 2.7 x 10-6 mol L-1. Some voltammograms of FLV solutions in the 
linear  range  are  shown  in  Fig.  2.  In  Table  2,  several  characteristics  of 
the calibration plot, as well as the LOD and LOQ calculated using this 
plot, are indicated. 
Results of precision and accuracy studies, presented in Table 3, 
confirm that the method is precise, accurate, and selective for the analysis 
of FLV. 
The method was applied to the quantification of FLV in Lescol. 
Analyses were preformed using five standard additions between 0  and 
1.3 x 10-7 mol L-1, obtaining a result of 20.04 ± 0.05 mg=capsule (n ¼ 3). 
  
 
 
Figure 2.  SWAdSV voltammograms of FLV solutions in the linear range. [FLV] 
(mol L-1): 1.0 x 10-8, 5.0 x 10-7, 1.3 x 10-6, 1.9 x 10-6, and 2.7 x 10-6. 
 
Flow-Injection  Analysis  with Amperometric  Detection (FIA-EC) 
 
An FIA-EC method for FLV determination in a pharmaceutical product 
was also developed. The method is based on FLV oxidation in a pH 10.0 
 
Table 2. Analytical data from the calibration plot in the determination of FLV by 
SWAdSV and FIA-EC 
 
 
Parameter SWAdSV FIA-EC 
 
 
Linear range (mol L-1) 1.0 x 10-8  to 
2.7 x 10-6 
1.0 x 10-6  to 
1.0 x 10-5 
n 13 6 
Correlation coefficient 0.999 0.999 
Slope of calibration 
plot (A mol L-1)-1 
2.460 0.0620 
Standard error slope 0.004 0.0008 
Intercept (nA) 255 -2.90 
Standard error intercept 8 243 
LOD (nmol L-1) 9.9  5.02 
LOQ (nmol L-1) 33  810 
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Table 3. Results from evaluation of the precision and accuracya 
 
 
Property SWAdSV FIA-EC 
 
 
Repeatability  (RSD %) 0.61 (0.1) 5.1 (2.0) 
1.1 (1.3) 4.3 (5.0) 
0.77 (2.5) 1.4 (8.0) 
Intermediate  precision (RSD %) 5.0 (0.1) 7.1 (2.0) 
4.1 (1.3) 2.0 (5.0) 
0.51 (2.5) 3.9 (8.0) 
Recovery (%) 96.8 ± 2.4 (0.4) 99.5 ± 6.1 (1.0) 
98.0 ± 1.3 (1.4) 99.0 ± 2.4 (4.0) 
103.8 ± 1.4 (2.4) 100.1 ± 2.8 (7.0) 
 
 
aConcentration in mmol=L are given in parentheses. 
 
Britton-Robinson buffer described in a previous work (Ozkan and Uslu 
2002). The oxidation current was monitored at a glassy carbon working 
electrode, and several experimental conditions were optimized to achieve 
the best relation among repeatability, reproducibility, sensitivity, sam- 
pling rate, and reagent consumption. The parameters optimized were 
the working electrode potential, the injection volume, the length of reac- 
tor, and the flow rate. This led to the following optimal conditions: 
E ¼ 1.0 V;  Vinj ¼ 238.6 mL;  reactor  length ¼ 18 cm;  and  flow  rate ¼ 
1.6 mL=min, achieving a sample rate of up to 50 injections per   hour. 
The frequently reported adsorption of the oxidation products on the 
electrode surface was also observed in this study. This adsorption leads to 
a lack of available surface and consequently a decrease of the analytical 
signal; therefore cleaning of the electrode surface was necessary. How- 
ever, flow systems minimize this problem because of the constant passage 
of the carrier stream, which helps to keep the electrode surface clean. In 
the present work, the electrode was polished only at the beginning of 
every working period. 
Under the optimal conditions, the amperometric signal is linear for 
FLV  concentrations  between  1.0 x 10-6 mol  L-1    and  1.0 x 10-5 mol 
L-1, with an LOD of 2.4 x 10-7 mol L-1  and an LOQ of 8.0 x 10-7 mol 
mol L-1. Calibration characteristics and the validation data are given in 
Tables  2  and  3  and  indicate  that  the  method  is  precise,  accurate,  and 
selective  for  FLV  analysis  in  the  tested  pharmaceutical  product.  In 
Figure 3, a fiagram of several FLV solutions with concentrations in the 
linear range is shown. 
The result of the quantification of FLV in the pharmaceutical pro- 
duct Lescol using the developed method was 20.3 ± 0.4 mg=capsule 
(n ¼ 3). 
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Figure  3.  Fiagram  of  various  FLV  solutions  in  the  linear  range.  [FLV]  (mmol 
L-1): 1.0, 2.0, 4.0, 6.0, 8.0, and 10. 
 
CONCLUSION 
 
Based on FLV’s electrochemical behavior, two easy and fast analytical 
methods were developed for its determination in a pharmaceutical pro- 
duct. SWAdSV and FIA-EC were successfully applied without interfer- 
ences from the excipients. Based on the linear ranges and limits of 
detection, both electroanalytical methodologies could be useful for the 
quantification of FLV in the tested product. Although the SWAdSV 
method presents higher sensitivity and a lower LOD, which can be useful 
for clinical analysis, the FIA-EC method presented a higher sample 
throughput, and its ease of automation could allow its  adoption  in 
routine  pharmaceutical  quality control. 
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